CTSH
Cognizant Technology Solutions Corporation
CTSH has lower modeled downside risk, despite its lower overall score.
SNDK
Sandisk Corporation
SNDK has the edge over CTSH overall, supported by stronger fundamentals and stronger modeled upside.
CTSH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
CTSH's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
SNDK Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
SNDK's revenue, profitability, cash flow and balance sheet are all currently strong.
CTSH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $63.75 | — |
| Current | 12x | $63.75 | — |
| Cheap | 14x | $75.47 | +18% |
| Fair | 17x | $92.95 | +46% |
| Expensive | 23x | $128 | +100% |
Historical ranges are pointers, not guarantees.
CTSH's PE is in its cheap range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings.
SNDK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.8x | $937 | — |
| Current | 7.5x | $937 | — |
| Cheap | 17x | $2,173 | +132% |
| Fair | 24x | $3,048 | +225% |
| Expensive | 59x | $7,452 | +695% |
Historical ranges are pointers, not guarantees.
SNDK has the edge over CTSH in the historical PE scenario, which offers more potential upside but is not a forecast.
CTSH Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Moderate | |
| High |
Analysts expect CTSH's earnings to grow and its profitability to improve, with its revenue holding steady.
SNDK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| High |
SNDK has the edge over CTSH on the outlook, with more favorable revenue expectations.
CTSH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.16 | +12% |
| Q3 2026 | $5.49 | +27% |
| Q2 2026 | $4.66 | -5.3% |
| Q1 2026 | $4.61 | -2.9% |
| Q4 2025 | $4.56 | +1.1% |
| Q3 2025 | $4.31 | -4.9% |
| Q2 2025 | $4.92 | +12% |
| Q1 2025 | $4.75 | +14% |
| Q4 2024 | $4.51 | +7.1% |
CTSH earned $5.49 per share over the past year, up 27% from the year before.
SNDK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $247.30 | +97% |
| Q3 2026 | $125.61 | +$137.63 |
| Q2 2026 | $73.76 | +$85.07 |
| Q2 2025 | -$11.31 | -$6.65 |
SNDK has the edge over CTSH in the latest year-over-year earnings comparison.
CTSH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.7B | +4.6% |
| Q2 2026 | $5.5B | +4.5% |
| Q1 2026 | $5.4B | +5.8% |
| Q4 2025 | $5.3B | +4.9% |
| Q3 2025 | $5.4B | +7.4% |
| Q2 2025 | $5.2B | +8.1% |
| Q1 2025 | $5.1B | +7.5% |
| Q4 2024 | $5.1B | +6.8% |
CTSH's revenue has grown year over year for nine quarters in a row: $5.7B last quarter, up 4.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | -0.6 points |
| Q2 2026 | 16% | +0.4 points |
| Q1 2026 | 16% | -1.1 points |
| Q4 2025 | 16% | +1.2 points |
| Q3 2025 | 16% | +1.4 points |
| Q2 2025 | 16% | +1 points |
| Q1 2025 | 17% | +2.1 points |
| Q4 2024 | 15% | -0.4 points |
CTSH's operating margin was 15% last quarter, down 0.6 points from the same quarter a year ago.
SNDK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11B | +378% |
| Q2 2026 | $9B | +372% |
| Q1 2026 | $6B | +251% |
| Q4 2025 | $3B | +61% |
| Q3 2025 | $2.3B | +23% |
| Q2 2025 | $1.9B | +8% |
| Q1 2025 | $1.7B | -0.6% |
| Q4 2024 | $1.9B | +13% |
SNDK's revenue has grown year over year for six quarters in a row: $11B last quarter, up 378% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 80% | +72 points |
| Q2 2026 | 78% | +78 points |
| Q1 2026 | 69% | +180 points |
| Q4 2025 | 35% | +25 points |
| Q3 2025 | 7.6% | -9 points |
| Q2 2025 | 0.9% | N/A |
| Q1 2025 | -111% | -122 points |
| Q4 2024 | 10% | +6.6 points |
SNDK has the edge over CTSH on profitability, with a higher operating margin.
CTSH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $925M | -20% |
| Q2 2026 | $459M | +39% |
| Q1 2026 | $198M | -39% |
| Q4 2025 | $781M | -6.7% |
| Q3 2025 | $1.2B | +47% |
| Q2 2025 | $331M | +81% |
| Q1 2025 | $323M | +1919% |
| Q4 2024 | $837M | +27% |
CTSH generated $2.4B in free cash flow over the past year, down 11% from the year before.
SNDK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.3B | +1340% |
| Q2 2026 | $7.1B | +14355% |
| Q1 2026 | $3B | +$3B |
| Q3 2025 | $438M | +$636M |
| Q2 2025 | $49M | +$217M |
| Q1 2025 | -$18M | +$23M |
| Q3 2024 | -$198M | -$157M |
SNDK has the edge over CTSH on cash flow, with more consistent year-over-year improvement.
CTSH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.4% | -16M shares |
| 1 year | -7.6% | -37M shares |
| 3 years | -11% | -55M shares |
| 5 years | -14% | -76M shares |
| Available history | -20% | -110M shares |
CTSH has the edge over SNDK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $270M |
| Q2 2026 | $1.2B |
| Q1 2026 | $444M |
| Q4 2025 | $338M |
| Q3 2025 | $463M |
| Q2 2025 | $368M |
| Q1 2025 | $209M |
| Q4 2024 | $154M |
CTSH spent $2.2B buying back its own shares over the past year, up 86% from the year before.
SNDK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -1M shares |
| 1 year | +3.4% | +5M shares |
| 3 years | +6.9% | +10M shares |
SNDK has 154M diluted shares, up 3.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5B |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
CTSH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.0x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | -0.2x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
CTSH's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
SNDK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
SNDK has the edge over CTSH on leverage, with a lower net debt burden relative to earnings.
CTSH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.9 | Neutral |
| Stochastic | 57.3 | Neutral |
CTSH's weekly RSI is 55 (neutral) and its Stochastic is 57 (neutral).
SNDK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.2 | Neutral |
| Stochastic | 10.6 | Oversold |
SNDK's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
CTSH PE vs Technology Sector
| Metric | CTSH | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 28x | 58% below |
| PE % | 3 | 35 | 32 pts below |
CTSH is trading at 12x earnings, a 58% discount to the Technology sector's median of 28x.
SNDK PE vs Technology Sector
| Metric | SNDK | Sector median | Relative |
|---|---|---|---|
| PE | 7.5x | 28x | 73% below |
| PE % | 4 | 27 | 23 pts below |
SNDK has the edge over CTSH on valuation relative to its sector.
CTSH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $63.2 | 1% above |
| 20 week MA | $58.0 | 9.9% above |
| 50 week MA | $62.4 | 2.1% above |
| 100 week MA | $69.0 | 7.6% below |
| 200 week MA | $69.5 | 8.3% below |
CTSH has stronger trend alignment. CTSH is above 3 of 5 weekly averages versus SNDK above 0 of 3.
SNDK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,317.5 | 29% below |
| 20 week MA | $1,465.4 | 36% below |
| 50 week MA | $1,119.6 | 16% below |
SNDK is in a downtrend: it's below all three of its weekly moving averages, and 16% below its 50-week average.
CTSH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.2 | $81.1 | +30% |
| 2021 | $81.1 | $86.3 | +6.4% |
| 2022 | $86.3 | $56.0 | -35% |
| 2023 | $56.0 | $75.5 | +35% |
| 2024 | $75.5 | $79.2 | +4.9% |
| 2025 | $79.2 | $85.6 | +8% |
| 2026 YTD | $85.6 | $63.8 | -25% |
CTSH has finished higher in five of the last six years. It's down 25% so far in 2026.
SNDK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $50.4 | $250.1 | +396% |
| 2026 YTD | $250.1 | $937.5 | +275% |
SNDK has the edge over CTSH on returns for 2026, with the stronger performance.